Immunologic Biomarker Profile of Cerebrospinal Fluid (BIOMOG)

Centre Hospitalier Universitaire de Nīmes

Status: Completed

Conditions: Neuromyelitis Optica; Multiple Sclerosis

Treatments: Other: Biomarker analysis

Study type: Observational

Funder types: Other

Identifiers

NCT04202055

NIMAO/2017-01/ET-01

Details and patient eligibility

About

The aim of this study was the describe the Immunologic biomarker profile of cerebrospinal fluid in multiple sclerosis patients

Enrollment: 165 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• patients who have had neuromyelitis ptica with anti-AQP4 antibodies, or anti- Myelin Oligodendrocyte Glycoprotein antibodies, or double seronegative antibodies.
• Neuromyelitis Optica patients have been prospectively included in the OFSEP collection
• Multiple sclerosis patients, isolated myelitis or optic neuritis patients, and symptomatic controls whose samples will come from the "NEURO" collection of the Hospital Biological Collections Center,
• Patients have given their free consent for use of their samples in research

Trial design

165 participants in 6 patient groups

Neuromyelitis optica with anti-MOG

Treatment:

Other: Biomarker analysis

Patients with Neuromyelitis optica with anti-AQP4

Treatment:

Other: Biomarker analysis

Seronegative patients with Neuromyelitis optica

Treatment:

Other: Biomarker analysis

Patients with recurrent-remitting multiple sclerosis

Description:

Patients with recurrent-remitting multiple sclerosis with medullary or optic involvement

Treatment:

Other: Biomarker analysis

Progressive multiple sclerosis patients

Treatment:

Other: Biomarker analysis

Symptomatic controls

Treatment:

Other: Biomarker analysis